Progenics Pharmaceuticals promoted Mark Baker to the newly created position of president. Baker will continue to report to Paul Maddon, the company’s founder. Baker will be responsible for overseeing the company’s commercial development, strategic planning, business development, communications, finance and accounting, operations and legal affairs, according to a company statement. He was also promoted to Progenics’ board of directors.
Swiss specialty pharma Addex Pharmaceuticals‘ head of business development Laurent Massuyeau has resigned, the company announced, without further explanation. He was also a member of the executive management team.
